Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | PLK1 | P53350 | 6/20 | 0.63 |
| ▸ | MMP13 | P45452 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208745 | 0.83 | HPGD (0.63) | HPGDTSHRHTTSMN1; SMN2PLK1 | |
| SCHEMBL10294125 | 0.81 | MLYCD (0.57) | HPGDTRPV1MAPTCYP1A2CYP2C19 | |
| SCHEMBL10294117 | 0.80 | EPHX2 (0.50) | HPGDSMN1; SMN2PLK1HDAC2EPHX2 | |
| SCHEMBL28093663 | 0.80 | HPGD (0.59) | HPGDTSHRHTTSMN1; SMN2PLK1 | |
| SCHEMBL20076975 | 0.79 | ELANE (0.60) | HPGDTSHRSMN1; SMN2MAPTCYP1A2 | |
| SCHEMBL13184545 | 0.79 | HPGD (1.00) | HPGDTSHRHTTSMN1; SMN2PLK1 | |
| SCHEMBL2645679 | 0.79 | HPGD (0.76) | HPGDTSHRHTTSMN1; SMN2PLK1 | |
| SCHEMBL28012461 | 0.79 | TRPV1 (0.65) | HPGDTSHRHTTSMN1; SMN2PLK1 | |
| SCHEMBL2733809 | 0.78 | CA1 (0.64) | TSHRSMN1; SMN2MAPTCA2CA1 | |
| SCHEMBL250247 | 0.78 | HDAC6 (0.80) | HPGDTSHRHTTSMN1; SMN2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172361-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CYP3A5, CYP11B2, ABCB1 | HPGD 1190/4885TSHR 129/4885HTT 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.